The two companies will co-develop and co-commercialize ODM-208, which is currently in a phase 2 clinical trial, but the contract allows for Merck to wield a global exclusive license if it wants to, according to a July 13 press release.
The treatment targets metastatic castration-resistant prostate cancer by focusing on subduing steroid hormones.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
